The MassARRAY SARS-CoV-2/Flu Panel from Agena Bioscience is a scalable, low-cost platform for qualitative and simultaneous detection of SARS-CoV-2, influenza A, and influenza B RNA, based on reverse transcriptase PCR (RT-PCR). The high-throughput capability can help laboratories process thousands of samples per day, which can free up staff time and resources. Additionally, access to reliable testing helps to streamline larger sample volumes.
The panel aims to ensure accurate detection by including dual SARS-CoV-2 targets for redundancy, and its pan-assay design detects all influenza A subtypes (including H1N1 and H3N2) and influenza B lineages. Agena aims to secure a reliable supply, with immediate availability of instruments and reagents.

Agena Bioscience